HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XCUR
Exicure, Inc.
There isn't enough reported data to score XCUR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XCUR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
XCUR's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XCUR PE Valuation
XCUR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XCUR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect XCUR's losses to grow, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XCUR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.34 | +$2.48 |
| Q1 2026 | -$1.57 | +$2.19 |
| Q4 2025 | -$0.79 | +$3.96 |
| Q3 2025 | -$3.64 | -$1.62 |
| Q2 2025 | -$3.82 | +$0.68 |
| Q1 2025 | -$3.76 | +$3.79 |
| Q4 2024 | -$4.75 | +$5.80 |
| Q3 2024 | -$2.02 | -118% |
XCUR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XCUR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XCUR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $21.8M | +928% |
| Q2 2022 | $2.5M | +3028% |
| Q1 2022 | $2.6M | +157% |
| Q4 2021 | $2.1M | +1413% |
| Q2 2021 | $79K | -98% |
| Q1 2021 | $997K | -89% |
| Q4 2020 | $140K | -55% |
| Q3 2020 | $2.4M | +364% |
XCUR's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -167% | N/A |
| Q4 2022 | 85% | +720 points |
| Q3 2022 | -258% | N/A |
| Q2 2022 | -303% | +17244 points |
| Q1 2022 | -302% | +918 points |
| Q4 2021 | -635% | +8265 points |
| Q2 2021 | -17547% | -17456 points |
| Q1 2021 | -1219% | -1225 points |
XCUR's operating margin was −167% last quarter, up 134 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
XCUR has the stronger cash trend. Its trailing FCF is up 68% versus its history, compared with HIMS at down 84%.
XCUR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.1M | +$456K |
| Q4 2025 | -$934K | -$89K |
| Q3 2025 | -$3.4M | -$3M |
| Q1 2025 | -$1.6M | -$1.1M |
| Q4 2024 | -$845K | -$29K |
| Q3 2024 | -$449K | +$963K |
| Q2 2024 | -$1.2M | +$3.6M |
| Q1 2024 | -$450K | +$2.9M |
XCUR has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XCUR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XCUR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +25 shares |
| 1 year | +0.9% | +56.2K shares |
| 3 years | +278% | +4.7M shares |
| 5 years | +996% | +5.8M shares |
| Available history | +1379% | +5.9M shares |
XCUR has 6M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | $9,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XCUR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.2x | Net Cash |
| Q2 2023 | -0.6x | Net Cash |
| Q1 2023 | -4.0x | Net Cash |
XCUR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XCUR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.4 | Neutral |
| Stochastic | 20.3 | Neutral |
XCUR's weekly RSI is 31 (neutral) and its Stochastic is 20 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XCUR PE vs Healthcare Sector
| Metric | XCUR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XCUR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XCUR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 1.9% below |
| 20 week MA | $1.31 | 19% below |
| 50 week MA | $3.02 | 65% below |
| 100 week MA | $5.82 | 82% below |
| 200 week MA | $5.12 | 79% below |
XCUR is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over XCUR on returns for 2026, with the stronger performance.
XCUR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $289.5 | -31% |
| 2021 | $289.5 | $32.6 | -89% |
| 2022 | $32.6 | $6.40 | -80% |
| 2023 | $6.40 | $2.90 | -55% |
| 2024 | $2.90 | $17.6 | +506% |
| 2025 | $17.6 | $5.99 | -66% |
| 2026 YTD | $5.99 | $1.06 | -82% |
XCUR's yearly returns have swung widely, from +506% in 2024 to −89% in 2021. It's down 82% so far in 2026.